Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Soliqua vs Glargine + Gliclazide in South Asian T2DM
NCT03819790Phase 4Completed
- Sponsor
- LMC Diabetes & Endocrinology
- Start
- Oct 2018
- Primary completion
- Nov 2019
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 4 trial of insulin glargine + lixisenatide in type 2 diabetes mellitus (T2DM), sponsored by LMC Diabetes & Endocrinology. Started Oct 2018; status: completed.
02
Drugs
insulin glargine + lixisenatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03819790.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03819790.